Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.88 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.88 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.77 |
| ▸ | MEN1 | O00255 | 5/20 | 0.77 |
| ▸ | PKM | P14618 | 1/20 | 0.76 |
| ▸ | POLB | P06746 | 2/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.59 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11363579 | 0.93 | ALDH1A1 (1.00) | ALDH1A1CYP2C9CYP2C19KMT2AMEN1 | |
| SCHEMBL27630121 | 0.90 | ALDH1A1 (0.84) | ALDH1A1CYP2C9CYP2C19KMT2AMEN1 | |
| SCHEMBL3617781 | 0.89 | KMT2A (0.83) | ALDH1A1CYP2C9CYP2C19KMT2AMEN1 | |
| SCHEMBL28756893 | 0.88 | KMT2A (0.82) | ALDH1A1CYP2C9CYP2C19KMT2AMEN1 | |
| SCHEMBL3619889 | 0.87 | KMT2A (0.80) | ALDH1A1CYP2C9CYP2C19KMT2AMEN1 | |
| SCHEMBL27630068 | 0.87 | KMT2A (0.80) | ALDH1A1CYP2C9CYP2C19KMT2AMEN1 | |
| SCHEMBL27650147 | 0.87 | KMT2A (1.00) | ALDH1A1CYP2C9CYP2C19KMT2AMEN1 | |
| SCHEMBL3620152 | 0.87 | KMT2A (1.00) | ALDH1A1CYP2C9CYP2C19KMT2AMEN1 | |
| SCHEMBL27650007 | 0.86 | PKM (1.00) | ALDH1A1CYP2C9CYP2C19KMT2AMEN1 | |
| SCHEMBL3621762 | 0.85 | ALDH1A1 (0.64) | ALDH1A1CYP2C9CYP2C19KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2010-05-06 | — | — | US | claimed |
| US-7618961-B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2009-11-17 | — | — | US | claimed |
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2004-11-11 | — | — | US | claimed |
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2010-05-06 | — | — | US | disclosed |
| US-7618961-B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2009-11-17 | — | — | US | disclosed |
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | ALDH1A1 55/4885CYP2C9 179/4885CYP2C19 127/4885 |
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD3B1 | ALDH1A1 59/4885CYP2C9 194/4885CYP2C19 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.